• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar

Galen Institute

A not-for-profit health and tax policy research organization.

  • Home
  • About Us
    • Mission and History
    • Officers and Trustees
    • Scholars and Staff
    • Who was Galen?
  • Activities
    • Core Activities
    • State Leaders Calls
    • Commentary and Oped Tutorial
    • Our Book
    • Galen Guides
  • Donate
  • Contact Us
  • Major Papers
  • Broadcast Interviews
  • Health Policy Consensus Group

Avik Roy: How Margaret Hamburg’s FDA Causes Cancer Drug Shortages

POSTED BY Galen Institute on June 15, 2012.

One of the most serious problems in American health care today is acatastrophic shortage of supply for dozens of important generic drugs, especially certain injectable medications that form the backbone of modern cancer chemotherapy. As a result of the shortages, many cancer patients today are unable to gain access to basic, life-extending drugs that cost less than a bottle of Coke. Today, the House Oversight Committee released an in-depth report, alleging that a significant cause of this shortage is an out-of-control regulatory smackdown, initiated by FDA Commissioner Margaret Hamburg.

The report, commissioned by Oversight Committee chairman Darrell Issa (R., Calif.), details the dramatic drop in the production of generic injectable drugs since Hamburg was confirmed as FDA chief in May 2009. Upon taking office, Hamburg promised an aggressive effort to enforce the FDA’s stringent manufacturing standards. In 2010, Hamburg’s officials issued 673 warning letters to drugmakers and other companies: a 42 percent increase from 2009. In 2011, the agency issued 1,720 warning letters: a further increase of 156 percent.

Continue reading on Forbes…

Filed Under: Uncategorized

Primary Sidebar

Our Annual Report

Health Care Choices 20/20:

A Vision for the Future

SEARCH

LATEST NEWSLETTER ISSUES

SUBSCRIBE

Social Media

Like Us On Facebook

Twitter: @galeninstitute

 

Copyright Galen Institute, Inc © 2022; · Log in